title: Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Torjesen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use; D000068258:Bevacizumab; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D004739:England; D006801:Humans; D056687:Off-Label Use / Q000331:legislation & jurisprudence*; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab